Replies to post #20373 on Intellect Neurosciences Inc. (fka ILNS)

[tencoin]

Three studies have been developed in Phase 2, without any Public Release from CEO of ILNS, and without updating some pages of the website...
I did not check PFIZER's study ...
------------------------------------------------------------

1) SHIRE
More Information:
https://clinicaltrials.gov/ct2/show/results/NCT01898884?term=Friedreich%27s+Ataxia+shire&rank=1§=X61&view=results#more
Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed.

Restriction Description: If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution may publish results generated from the site individually.
---------------------------------------------------------------

2) Study of BMS-986168 in Patients With Progressive Supranuclear Palsy
https://clinicaltrials.gov/ct2/show/study/NCT03068468?term=BMS-986168&rank=1

Bristol-Myers Squibb: Phase 2
Anticipated Study Start Date: March 30, 2017
---------------------------------------------------------------

3) A Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects With Early Alzheimer's Disease
https://clinicaltrials.gov/ct2/show/NCT02880956?term=ABBV-8E12&rank=1

AbbVie: Phase 2
Study Start Date: October 2016
---------------------------------------------------------------

4) A Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Progressive Supranuclear Palsy
https://clinicaltrials.gov/ct2/show/NCT02985879?term=ABBV-8E12&rank=2

AbbVie: Phase 2
Study Start Date: December 2016
---------------------------------------------------------------




















































.